Glenn F. Tilton - Apr 28, 2023 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role: Director
Signature: Steven L. Scrogham, attorney-in-fact for Glenn F. Tilton
Stock symbol: ABBV
Transactions as of: Apr 28, 2023
Transactions value $: -$336,998
Form type: 4
Date filed: 5/2/2023, 05:17 PM
Previous filing: Jan 19, 2023
Next filing: May 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABBV	Stock Equivalent Units	Options Exercise	-$337K	-2.23K	-6.04%	$151.12	34.7K	Apr 28, 2023	Common Stock	2.23K	$151.12	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The cash equivalent of 2,230 AbbVie stock equivalent units in the Abbott account was paid to the director upon his retirement from Abbott's board on April 28, 2023.
F2	Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Content

The cash equivalent of 2,230 AbbVie stock equivalent units in the Abbott account was paid to the director upon his retirement from Abbott's board on April 28, 2023.

Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.